

## Made-in-Canada update from Minister Bains next week: SIF + IRAP vaccine projects

---

**From:** "Bildstein, Taylor (IC)" <"/o=canadacentdepl/ou=exchange administrative group (fydibohf23spdl)/cn=recipients/cn=f59c77ca20b54f96a921f162198db35b-taylor.bi">

**To:** "Tessier, Jean" <jean.tessier@pco-bcp.gc.ca>, "Butara, Frank" <frank.butara@pco-bcp.gc.ca>, "Martel, Camille (Ext.)" <camille.martel@pco-bcp.gc.ca>, "Charlebois, Philippe" <philippe.charlebois@pco-bcp.gc.ca>, "Donovan, John (Ext.)" <john.donovan@pco-bcp.gc.ca>, "Maher, Brenna" <brenna.maher@pco-bcp.gc.ca>, "Mitchell, Heloise" <heloise.mitchell@pco-bcp.gc.ca>, "Bett, Jason (IC)" <jason.bett@canada.ca>, "MacKenzie, Sara (HC/SC)" <sara.mackenzie@canada.ca>, "Allison, Catherine (HC/SC)" <catherine.allison@canada.ca>, "Russo, Laura (HC/SC)" <laura.russo@canada.ca>, "Crowder, Cassandra (SAC/ISC)" <cassandra.crowder@canada.ca>, charles.mojsej@international.gc.ca, James Stott <james.stott@tpsgc-pwgsc.gc.ca>, Elizabeth Lindsay <elizabeth.lindsay@tpsgc-pwgsc.gc.ca>, "Sousa, Marcella (IC)" <marcella.sousa@canada.ca>, "Fasiolo, Raffaele" <raffaele.fasiolo@pco-bcp.gc.ca>

**Cc:** "Patterson - EXT, Adine (Ext.)" <adine.patterson@pco-bcp.gc.ca>

**Date:** Fri, 09 Oct 2020 14:20:19 +0000

**Attachments:** NR-Bains-Made in Canada update\_20-10-08.docx (48.45 kB)

---

Good morning,

Minister Bains is planning to make a Made-in-Canada update next week, which could be as early as Tuesday. The update will include the following vaccine announcements:

- A Strategic Innovation Fund investment of up to \$18.2 million in Vancouver-based biotechnology company [Precision NanoSystems Incorporated](#) (PNI) to help advance the development of a COVID-19 vaccine candidate through pre-clinical studies and clinical trials.
- Up to \$23.2 million in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to advance six COVID-19 vaccine candidates in various stages of clinical trials (details below).

A draft NR is attached for your awareness – please note that this is not final and Minister Bains' office has not provided feedback at this stage. Please do not circulate this draft NR.

Please don't hesitate to contact me if you have any questions.

Thank you,  
Taylor

**Taylor Bildstein**

Director, Ministerial Services / Directrice, Services ministériels  
Innovation, Science and Economic Development / Innovation, Sciences et Développement économique  
[Taylor.Bildstein@canada.ca](mailto:Taylor.Bildstein@canada.ca) Tel/Tél : 819-639-0983

---

-  
The National Research Council of Canada Industrial Research Assistance Program is providing advisory services and funding to advance six vaccine candidates, including up to:

- 
- \$5.4 million to Immunovaccine Technologies Inc. (Dartmouth, N.S.) for phase 2/3 clinical trials of its DPX-COVID19 vaccine candidate;
  - \$5.0 million to Entos Pharmaceuticals (Edmonton, Alta.) for phase 1 clinical trials of its Covigenix VAX-001 vaccine candidate;
  - \$4.7 million to Providence Therapeutics COVID Inc. (Toronto, Ont.) for phase 1 clinical trials of its PTX-COVID19-B mRNA vaccine candidate;
  - \$4.0 million to Glycovax Pharma (Montreal, Que.) for phase 1 clinical trials of its COVID-19 vaccine candidate;
  - \$2.8 million to Symvivo (Burnaby, B.C.) to advance its bacTRL-Spike oral DNA vaccine candidate in preclinical and phase 1 clinical trials;
  - \$1.3 million to Biodextris Inc. (Laval, Que.) for pre-clinical development of its nasal COVID-19 vaccine candidate.
- 
- 